Daniel C Adelman
Overview
Explore the profile of Daniel C Adelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chinthrajah R, Sindher S, Nadeau K, Leflein J, Spergel J, Petroni D, et al.
Allergy
. 2024 Dec;
80(3):827-842.
PMID: 39673367
Background: Peanut allergy is a common, life-threatening food allergy in children. We evaluated whether dupilumab, which blocks the activity of interleukin (IL)-4/IL-13, enhances the efficacy of oral immunotherapy (OIT) AR101...
2.
Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon L, et al.
J Allergy Clin Immunol
. 2023 Apr;
152(1):155-166.e9.
PMID: 37003475
Background: Despite similar clinical symptoms, peanut-allergic (PA) individuals may respond quite differently to the same therapeutic interventions. Objective: This study aimed to determine whether inherent qualities of cell response at...
3.
Ciaccio C, Goldsobel A, Anagnostou A, Beyer K, Casale T, Deschildre A, et al.
Ann Allergy Asthma Immunol
. 2022 Aug;
129(6):758-768.e4.
PMID: 35973655
Background: Clinical trials (PALISADE [ARC003], ARTEMIS [ARC010]) proving efficacy and safety of peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) have used double-blind, placebo-controlled food challenges (DBPCFCs) to screen for eligibility and...
4.
Bajzik V, DeBerg H, Garabatos N, Rust B, Obrien K, Nguyen Q, et al.
Allergy
. 2022 Mar;
77(8):2534-2548.
PMID: 35266148
Background: The PALISADE study, an international, phase 3 trial of peanut oral immunotherapy (POIT) with AR101, resulted in desensitization in children and adolescents who were highly allergic to peanut. An...
5.
Chinthrajah R, Jones S, Kim E, Sicherer S, Shreffler W, Lanser B, et al.
J Allergy Clin Immunol
. 2022 Jan;
149(6):2166-2170.e1.
PMID: 35026206
Background: Immunotherapy is promising as an efficacious treatment for food allergy. Other food allergy treatments are also under development. However, adverse allergic events during treatment, as well as during oral...
6.
Nilsson C, Scurlock A, Dellon E, Brostoff J, Pham T, Ryan R, et al.
J Allergy Clin Immunol Pract
. 2021 Aug;
9(12):4496-4501.
PMID: 34389504
No abstract available.
7.
Fernandez-Rivas M, Vereda A, Vickery B, Sharma V, Nilsson C, Muraro A, et al.
Allergy
. 2021 Jul;
77(3):991-1003.
PMID: 34320250
Background: The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials, but limited data past the first year of treatment are available....
8.
Patel N, Adelman D, Anagnostou K, Baumert J, Blom W, Campbell D, et al.
J Allergy Clin Immunol
. 2021 Feb;
147(6):2249-2262.e7.
PMID: 33571537
Background: Eliciting doses (EDs) (eg, ED or ED values, which are the amounts of allergen expected to cause objective symptoms in 1% and 5% of the population with an allergy,...
9.
Vickery B, Vereda A, Nilsson C, Du Toit G, Shreffler W, Burks A, et al.
J Allergy Clin Immunol Pract
. 2020 Dec;
9(5):1879-1889.e13.
PMID: 33359589
Background: The randomized, controlled PALISADE trial demonstrated the benefit of daily oral immunotherapy with Peanut (Arachis Hypogaea) allergen powder-dnfp (PTAH, formerly AR101) in peanut-allergic children and adolescents. Objective: ARC004, the...
10.
OB Hourihane J, Beyer K, Abbas A, Fernandez-Rivas M, Turner P, Blumchen K, et al.
Lancet Child Adolesc Health
. 2020 Jul;
4(10):728-739.
PMID: 32702315
Background: Peanut allergy is the leading cause of food-related anaphylaxis. Current management options can negatively affect food allergy-related quality of life. We aimed to investigate the efficacy of an investigational...